FTC points to Martin Shkreli's livestreams and stock trades as breaches of a lifetime pharma ban
FTC and seven state attorneys general asked a federal judge to hold Martin Shkreli in contempt for allegedly breaking his 2022 lifetime pharma ban. The filing treats his livestreamed commentary on the industry as a breach alongside his trading.
The Product Desk
Seven states from the FTC's Daraprim suit join the filing. The ban bars owning pharma stock and statements that could sway business. The FTC alleges trades in stocks of at least 60 pharma firms and livestream short campaigns, and seeks a profits fine and escalating penalties.
- precedent Seven states The same states that joined the FTC in suing Shkreli over the Daraprim scheme, claim 2
- constraint Shkreli's stock ownership Ban bars owning pharma stock and statements that could sway a company's business, per FTC and states, claim 9
- exposure Shkreli's trading FTC alleges he has publicly traded stocks of at least 60 pharmaceutical companies since his release, claim 5
- exposure Shkreli's livestreams FTC alleges he used them to wage public campaigns to short certain pharmaceutical company stocks, claim 8
- cost Shkreli's trading profits Proposed FTC fine equals his pharma trading profits plus prejudgment interest, with no offset for losses, claim 4
- decision Future violations FTC and states seek clear and escalating consequences, including further penalties and incarceration, claim 3
| Who | How | Kind | Claim |
|---|---|---|---|
| Seven states | The same states that joined the FTC in suing Shkreli over the Daraprim scheme | precedent | 2 |
| Shkreli's stock ownership | Ban bars owning pharma stock and statements that could sway a company's business, per FTC and states | constraint | 9 |
| Shkreli's trading | FTC alleges he has publicly traded stocks of at least 60 pharmaceutical companies since his release | exposure | 5 |
| Shkreli's livestreams | FTC alleges he used them to wage public campaigns to short certain pharmaceutical company stocks | exposure | 8 |
| Shkreli's trading profits | Proposed FTC fine equals his pharma trading profits plus prejudgment interest, with no offset for losses | cost | 4 |
| Future violations | FTC and states seek clear and escalating consequences, including further penalties and incarceration | decision | 3 |
What happened
- The seven states are New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia, the same ones that joined the FTC's 2020 suit over Daraprim.
- The FTC alleges that since his release Shkreli has publicly traded stocks of at least 60 pharmaceutical companies and broadcast his opinions on the business and management of many of them.
- Ars Technica reports that the FTC and the states say he has broken the ban "flagrantly and repeatedly" for nearly the entire time it has applied.
- They want him to divest from all pharmaceutical companies, pay a fine equal to his trading profits, and face escalating consequences for future violations, including incarceration.
- Shkreli did not immediately respond to questions Gizmodo emailed on Tuesday.
Why it matters
- constraint Enforcing a ban with one limb on holdings and one on public statements takes two records: trades and broadcasts. A team that holds only one of them sees only part of the breach.
- cost The proposed fine is measured on trading profits plus prejudgment interest with no credit for losing trades, so Shkreli's exposure follows his winning trades, whatever his net result.
- precedent If the judge grants the escalating-consequences request, any later breach would be answered under penalties set in advance, including incarceration.
According to the FTC, Martin Shkreli said on one of his livestreams: "I'm showing you how to trade and invest in biotech." [7] Shkreli pitched the stream as trading instruction; the FTC alleges he used his livestreams "to wage multiple public campaigns to short certain pharmaceutical company stocks based on his prediction that their key clinical trials would fail." [8]
The order he is accused of breaking has two limbs. The FTC and the states say it "explicitly prohibits" Shkreli from owning stock in pharmaceutical companies and from making public statements that could influence a pharmaceutical company's business. [9] The court that imposed it in 2022 said his "egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct" warranted an injunction of that scope. [10]
The order, as the FTC and states describe it, lists statements that could influence a company's business as an item separate from owning stock, so the streams are at issue on their own, apart from the trades. [9]
"Today's action should serve as notice that the FTC will not hesitate to enforce violations of court orders," said Daniel Guarnera, Director of the FTC's Bureau of Competition. [11] These are allegations in a request to the court, and neither report describes a ruling.
The two outlets disagree on where Daraprim's price started. Ars Technica puts it at $17.50 a pill and Gizmodo at $13.50, both ending at $750. [13][14] Ars's phrase "more than 4,000 percent" fits its own figure: $750 over $17.50 is a rise of about 4,190 percent. [15] From $13.50 it would be about 5,460 percent. [16]
For anyone who has to monitor a person or account under a restriction with both limbs, we'd sort on two questions: does the person hold a position in the company, and does the person address an audience about it. Position and audience: review first, because that is the cell where the FTC's short-campaign allegation sits. Position only: review the trade log. Audience only: review the content, since the order here treats influential statements as a separate item from owning stock. Neither: no action. The cost of that sort is that the audience cells need a person to watch or transcribe streams, and the position cells need only a log.
What to watch
- Shkreli's answer to the court, including whether he disputes that his streams count as statements that could influence a pharmaceutical company's business.
- Whether the judge adopts the fine formula with no offset for losses, since it fixes the size of his exposure.
- Whether the court writes specific penalties, including incarceration, into an order for any future violation.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence55
- Adoption
- Insufficient
- Hype gap+10
- Incentives40
- Confidence70
Perspective Coverage
3 publishers- Builder
- Builder 5%
- Operator
- Operator 38%
- Investor
- Investor 57%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
The FTC and the attorneys general of seven states asked a federal judge on Tuesday to hold Martin Shkreli in contempt for alleged violations of his lifetime ban from the pharmaceutical industry, imposed in 2022.
- [2]
The seven states are New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia, the same states that joined the FTC in suing Shkreli in 2020 over the Daraprim scheme.
- [3]
The FTC and the states seek to force Shkreli to divest from all pharmaceutical companies and pay a fine equal to his profits from trading pharmaceutical company stocks, and want the court to set 'clear and escalating consequences' for future violations, including further financial penalties and incarceration.
- [4]
The FTC's proposed fine equals his profits from any pharmaceutical company stock trading, plus prejudgment interest, without the ability to account for offsetting losses.
- [5]
The FTC alleges that since his release Shkreli has been publicly trading in pharmaceutical industry stocks of at least 60 companies and broadcasting online his opinions about the business and management of many pharmaceutical companies.
- [6]
The FTC and the seven states say Shkreli has 'flagrantly and repeatedly' violated the ban nearly the entire time it has been in place.
- [7]
The FTC quotes Shkreli saying on one of his livestreams: "I'm showing you how to trade and invest in biotech."
- [8]
The FTC alleges Shkreli 'used his livestreams to wage multiple public campaigns to short certain pharmaceutical company stocks based on his prediction that their key clinical trials would fail.'
- [9]
According to the FTC and the states, the ban 'explicitly prohibits' Shkreli from owning stock in pharmaceutical companies and making public statements that could influence a pharmaceutical company's business.
- [10]
In 2022 the federal court ruled that 'Shkreli's egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct warrants imposition of an injunction of this scope.'
- [11]
"Today's action should serve as notice that the FTC will not hesitate to enforce violations of court orders," said Daniel Guarnera, Director of the FTC's Bureau of Competition.
- [12]
Shkreli did not immediately respond to questions emailed Tuesday.
- [13]
Ars Technica reports the Daraprim price rose from $17.50 per pill to $750 per pill and describes the increase as more than 4,000 percent.
- [14]
Gizmodo reports Shkreli raised the price of Daraprim from $13.50 to $750 a pill.
- [15]
A rise from $17.50 to $750 is about 4,190 percent.
- [16]
A rise from $13.50 to $750 is about 5,460 percent.
Sources
3 independent publishers whose own reporting we read for this story.
- arstechnica.comMartin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
1 article · October 13, 2026
- gizmodo.comPharma Bro Martin Shkreli Could Be in Big Trouble Again
1 article · October 13, 2026
- statnews.comSTAT+: FTC demands Martin Shkreli divest his pharma stocks
1 article · October 13, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
Entities
- DaraprimFollow
- Martin ShkreliFollow
- Federal Trade CommissionFollow
- Daniel GuarneraFollow